Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Machine-learning model spots autism-linked variants that scramble splicing
The model provides a way to investigate genetic variation in regions of the genome whose functions have been difficult to interpret.
Machine-learning model spots autism-linked variants that scramble splicing
The model provides a way to investigate genetic variation in regions of the genome whose functions have been difficult to interpret.
Future of AI brain models sparks debate
Neuroscientists are divided about whether foundation models that predict brain responses will help the field understand how brains work.
Future of AI brain models sparks debate
Neuroscientists are divided about whether foundation models that predict brain responses will help the field understand how brains work.
Language development during the first 1,000 days; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 9 November.
Language development during the first 1,000 days; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 9 November.